Nitroaromatic acids, ubiquitous intermediates in nitro compounds, find broad applications in pharmaceuticals and fine chemical industries, yet their safety often receives inadequate attention. This ...
Highlights Fourth quarter 2024 net income of $10.7 million, or $0.09 per diluted share Quarterly adjusted EBITDA of $193.4 million CLAYTON, Mo., Jan. 30, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback